| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Common Stock | Sale | $10,345 | -51 | -1.1% | $202.84 | 4,703 | 30 Sep 2021 | Direct | F1, F2 |
| transaction | NVAX | Common Stock | Sale | $11,217 | -55 | -1.2% | $203.94 | 4,648 | 30 Sep 2021 | Direct | F1, F3 |
| transaction | NVAX | Common Stock | Sale | $3,280 | -16 | -0.34% | $205.01 | 4,632 | 30 Sep 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Sale | $57,962 | -280 | -6% | $207.01 | 4,352 | 30 Sep 2021 | Direct | F1, F4 |
| transaction | NVAX | Common Stock | Sale | $24,335 | -117 | -2.7% | $207.99 | 4,235 | 30 Sep 2021 | Direct | F1, F5 |
| transaction | NVAX | Common Stock | Sale | $24,694 | -118 | -2.8% | $209.27 | 4,117 | 30 Sep 2021 | Direct | F1, F6 |
| transaction | NVAX | Common Stock | Sale | $8,406 | -40 | -0.97% | $210.16 | 4,077 | 30 Sep 2021 | Direct | F1, F7 |
| transaction | NVAX | Common Stock | Sale | $3,382 | -16 | -0.39% | $211.39 | 4,061 | 30 Sep 2021 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.49 to $203.31, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F3 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.67 to $204.31, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F4 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.58 to $207.50, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F5 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.75 to $208.38, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F6 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.76 to $209.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F7 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.08 to $210.35, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |